A -- EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MODELS

Notice Date

May 3, 2001

Contracting Office

National Cancer Institute, Research Contracts Branch, PCPSS, Executive Plaza South, Room 635, Bethesda, Md 20892

ZIP Code

20892

Solicitation Number

RFP/MAO-N01-CN-15011-72

Response Due

June 21, 2001

Point of Contact

Jacqueline Ballard, Contracting Officer, 301-435-3795

E-Mail Address

Jacqueline Ballard (ballardj@mail.nih.gov.)

Description

The National Cancer Institute, Division of Cancer Prevention, (DCP) Chemoprevention Agent Development Research Group (CADRG) is interested in evaluating inhibitors or potential inhibitors of any stage of carcinogenesis, in order to identify potential chemopreventive agents. Such agents are to be further evaluated in appropriate toxicological and/or clinical settings. The CADRG has established a clearly defined integrated plan for the evaluation of chemopreventive agents. This plan delineates detailed criteria for classifying the quantity and quality of information that currently exists on any chemopreventive agent and thus defines what additional information and investigations are required to qualify the agent's experimental use in intervention trials of human cancer. The primary purpose of this RFP is to further evaluate chemopreventive agents for which there exists at least one published report regarding their effectiveness in inhibiting carcinogenesis. The object of these studies is to establish the general efficacy of the chemopreventive agent in animal model systems representing selected target organs, different species, and different carcinogens. This RFP involves multiple Workstatements (Nos. 87-91). Certain study design characteristics apply to the specific Workstatements under this RFP. Most of the requirements for the Workstatement study design will be detailed in the specific workstatement. Each workstatement will have a specific period of performance. The workstatements are: WS #87: Efficacy Testing in the Strain A Mouse Lung Tumor Model with Selected Chemopreventive Agents Administered by Aerosols; WS #88: Chemoprevention of azoxymethane induced foci of aberrant crypts in colons of rats treated with selected chemopreventive agents; WS #89: Ptch-/+ heterozygous mice over expressing ODC: A chemoprevention model for basal cell carcinoma; WS #90: Chemopreventive Agent Efficacy Using Chemically Induced Prostate Carcinogenesis in Rats; WS #91: Evaluation of candidate chemopreventive agents for their efficacy to induce regression of established intraepithelial neoplasia in rat esophagus using optical photospectroscopy analysis. This RFP/MAO will be available electronically to all the current Master Agreement Holders. Those interested in obtaining a copy of this RFP should send their e-mail address to Jacqueline Ballard at ballardj@mail.nih.gov and a copy of the RFP will be forwarded electronically. Proposals will only be considered from offerors in the Efficacy Studies Pool. AWARDS WILL ONLY BE MADE TO A MASTER AGREEMENT HOLDER WHO IS CURRENTLY IN THE EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MODELS POOL. For those who are not currently in the Master Agreement Pool who wish to be considered for inclusion should consult the Research Contracts Branch website at http://rcb.nci.nih.gov. under "Current Requests for Proposals" and refer to RFP-MA-N01-CN-85051-72 for instructions on submitting a proposal for consideration under the Master Agreement. The duration of the existing Master Agreement Pool is through December 29, 2002. The annual due date for proposals is April 1 of each year for those interested in being included in the projected annual review. It is the offeror's responsibility to monitor the above internet site for the release of this solicitation and amendment, if any. All Offerors are responsible for downloading their own copy of the solicitation and amendment. (Hard copies will be available only upon individual request). In order to be considered for award, all offerors shall be holders of an Efficacy Studies of Chemopreventive Agents in Animal Models Master Agreement and members of this pool as of the May 21, 2001 release date of this RFP. It is anticipated that RFP/MAO-N01-CN-15011-72 will be available on or before May 21, 2001. All questions should be directed, via facsimile or e-mail to Jacqueline Ballard, Contracting Officer, Prevention and Control Population Sciences Contracts Section, Research Contracts Branch, National Cancer Institute, NIH, Executive Plaza South, Room 635, 6120 Executive Boulevard, MSC 7226 Rockville, Md. 20852. Phone: 301-435-3795; Fax: 301-402-8579; Email address: ballardj@mail.nih.gov. The North American Industry Classification System (NAICS) code is 54171. All request should reference the RFP No. N01-CN-15112-72. No collect calls will be accepted. Number Note 26 -- Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

Web Link

http://rcb.nci.nih.gov/ncics/rfps_published.asp (http://rcb.nci.nih.gov/ncics/rfps_published.asp)

Record

Loren Data Corp. 20010507/ASOL001.HTM (W-123 SN50L0L5)